1196 related articles for article (PubMed ID: 18172313)
1. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
2. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
Joshi S; Singh AR; Durden DL
Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
[TBL] [Abstract][Full Text] [Related]
3. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL
Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874
[TBL] [Abstract][Full Text] [Related]
4. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.
Mahadevan D; Chiorean EG; Harris WB; Von Hoff DD; Stejskal-Barnett A; Qi W; Anthony SP; Younger AE; Rensvold DM; Cordova F; Shelton CF; Becker MD; Garlich JR; Durden DL; Ramanathan RK
Eur J Cancer; 2012 Dec; 48(18):3319-27. PubMed ID: 22921184
[TBL] [Abstract][Full Text] [Related]
7. An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
De P; Dey N; Terakedis B; Bergsagel PL; Li ZH; Mahadevan D; Garlich JR; Trudel S; Makale MT; Durden DL
Cancer Chemother Pharmacol; 2013 Apr; 71(4):867-81. PubMed ID: 23355037
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.
Ozbay T; Durden DL; Liu T; O'Regan RM; Nahta R
Cancer Chemother Pharmacol; 2010 Mar; 65(4):697-706. PubMed ID: 19636556
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
10. Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo.
Qin AC; Li Y; Zhou LN; Xing CG; Lu XS
Cell Physiol Biochem; 2019; 52(4):758-768. PubMed ID: 30933440
[TBL] [Abstract][Full Text] [Related]
11. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
12. PTEN and phosphatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment.
Su JD; Mayo LD; Donner DB; Durden DL
Cancer Res; 2003 Jul; 63(13):3585-92. PubMed ID: 12839945
[TBL] [Abstract][Full Text] [Related]
13. Augmented Antitumor Activity for Novel Dual PI3K/BDR4 Inhibitors, SF2523 and SF1126 in Ewing Sarcoma.
Goldin AN; Singh A; Joshi S; Jamieson C; Durden DL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e304-e311. PubMed ID: 33480647
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Baiz D; Pinder TA; Hassan S; Karpova Y; Salsbury F; Welker ME; Kulik G
J Med Chem; 2012 Sep; 55(18):8038-46. PubMed ID: 22924393
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors.
Morales GA; Garlich JR; Su J; Peng X; Newblom J; Weber K; Durden DL
J Med Chem; 2013 Mar; 56(5):1922-39. PubMed ID: 23410005
[TBL] [Abstract][Full Text] [Related]
16. Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Deng M; Wang J; Chen Y; Zhang L; Liu D
Anticancer Drugs; 2015 Apr; 26(4):422-7. PubMed ID: 25588160
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
18. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Wong TW; Lee FY; Emanuel S; Fairchild C; Fargnoli J; Fink B; Gavai A; Hammell A; Henley B; Hilt C; Hunt JT; Krishnan B; Kukral D; Lewin A; Malone H; Norris D; Oppenheimer S; Vite G; Yu C
Clin Cancer Res; 2011 Jun; 17(12):4031-41. PubMed ID: 21531814
[TBL] [Abstract][Full Text] [Related]
20. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
